
Opinion|Videos|September 18, 2024
Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
GLP-1s More Effective at Preventing Colorectal Cancer Than Aspirin
2
Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug
3
CDC Vaccine Rollback Highlights Gaps in Public Understanding of Shared Decision-Making
4
Telemedicine Utilization and Preventive Services Among a Rural Population
5



























































